Studies conducted to date clearly indicate that IQOS is likely to present less risk of harm compared to smoking
The research was conducted in line with internationally respected
guidelines for clinical trials, such as Good Clinical Practice as
defined by the
PMI’s research program to confirm the risk reduction potential of IQOS includes laboratory and clinical studies, research on actual product use, and evaluation of how well smokers understand communications related to reduced risk. This and a related study are the latest of an eight-part clinical research program completed on IQOS to support reduced exposure and preliminary improvements in health outcomes. A one-year study with about 1,000 participants is currently ongoing to further support the current strong indications of risk reduction.
PMI’s Chief Medical Officer, Dr.
PMI is committed to replacing cigarettes with smoke-free products as
soon as possible to the benefit of smokers, society and public health.
Over 1.4 million smokers have already switched to IQOS, and the
company has plans to expand commercialization to key cities in 30-35
countries by the end of 2017. Since 2008, PMI has hired over 400
scientists and experts and invested over
The study is available on www.pmiscience.com.
Philip Morris International media office
T: +41 (0)58 242 4500